BCM
NKTR icon

Bodri Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Bodri Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-6,667
Closed -$1.1M – 49
2015
Q1 		$1.1M Buy
+6,667
New +$1.37M 0.59% 41
2014
Q4 		– Sell
-16,667
Closed -$3.02M – 64
2014
Q3 		$3.02M Buy
16,667
+144
+0.9% +$27.6K 1.46% 28
2014
Q2 		$3.18M Buy
+16,523
New +$2.92M 1.64% 20

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Bodri Capital Management's NKTR Position: Q2 2015 in Review

Bodri Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2015, closing a stake of 6,667 shares — an estimated $1.1M sold.

Bodri Capital Management first reported a position in NKTR in Q2 2014 and held it in 3 quarters. The position peaked at $3.18M in Q2 2014. 181 funds tracked by Wall St. Rank hold NKTR as of Q2 2015.

  • Bodri Capital Management reported no remaining Nektar Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Bodri Capital Management sold 6,667 Nektar Therapeutics shares in Q2 2015, an estimated $1.1M.
  • Bodri Capital Management first reported a position in Nektar Therapeutics in Q2 2014 and held it in 3 quarters.
  • Bodri Capital Management's Nektar Therapeutics position peaked at $3.18M in Q2 2014.
  • 181 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2015.

Based on Bodri Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.